Adimmune Corporation (4142.TW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Chi-Hsien Chan | CEO & Chairman | 67.32M | -- | -- |
| Mr. Chung-Cheng Liu | President, GM & Director | 4.65M | -- | -- |
| Mr. Chin-Chuan Chang | COO and VP of R&D | 5.74M | -- | -- |
| Mr. Fei Pan | Chief Legal Officer & General Counsel | 5.25M | -- | -- |
| Mr. Yin-Teng Chang | Chief Financial Officer | -- | -- | -- |
| Ms. Li-Ya Tang | Director of Administration Center | -- | -- | -- |
| Chih-Hsiang Leng | Head of R&D Division | -- | -- | -- |
| Mr. Chin-I Chiu | Vice President of Quality Assurance Department | 5.63M | -- | -- |
| Cheng Liu Churg | Acting R&D Officer | -- | -- | -- |
Adimmune Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
Corporate Governance
Upcoming Events
August 11, 2025 at 10:59 AM UTC - August 15, 2025 at 12:00 PM UTC
Adimmune Corporation Earnings Date
Recent Events
September 14, 2021 at 12:00 AM UTC
Ex-Dividend Date